초록

A method for treating multiple myeloma in a subject by administering 17-allylamino-17-demethoxy-geldanamycin or 17-amino geldanamycin, or a prodrug of either 17-AAG or 17-AG, to the subject.

대표청구항 ▼

What is claimed is: 1. A method of treating multiple myeloma (MM) in a subject in need of such treatment, comprising the step of administering to said subject a pharmaceutical formulation comprising a therapeutically effective dose of 17-allylamino-17-demethoxygeldanamycin (17-AAG) or 17-aminogelda

What is claimed is: 1. A method of treating multiple myeloma (MM) in a subject in need of such treatment, comprising the step of administering to said subject a pharmaceutical formulation comprising a therapeutically effective dose of 17-allylamino-17-demethoxygeldanamycin (17-AAG) or 17-aminogeldanamycin (17-AG), and optionally a pharmaceutically acceptable carrier or diluent, and optionally repeating said administering step until no further therapeutic benefit is obtained, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AAG, or an equivalent amount of 17-AG and results in an AUCtotal of 17-AAG per dose in the range of about 12,500 to about 20,000 ng/mL*h and/or an AUCtotal of 17-AG per dose in the range of about 5,000 ng/mL*h to about 18,000 ng/mL*h. 2. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject multiple doses of 17-AAG or 17-AG to said patient over a time period of at least 2 weeks, wherein each such dose is in the range of about 275 to about 420 mg/m2 of 17-AAG, or an equivalent amount of 17-AG that results in an AUCtotal of 17-AAG per dose in the range of about 12,500 to about 20,000 ng/mL*h and/or an AUCtotal of 17-AG per dose in the range of about 5,000 ng/mL*h to about 18,000 ng/mL*h. 3. The method of claim 2, wherein each dose of 17-AAG is about 340 mg/m2 or an equivalent amount of 17-AG. 4. The method of claim 2, wherein said dose is administered twice weekly for at least two weeks. 5. The method of claim 4, wherein said dose is administered twice weekly for at least two weeks in a three week period. 6. The method of claim 5, wherein multiple cycles of treatment are administered to the subject, wherein each cycle of treatment comprises of said dose administered twice weekly for at least two weeks in a three week period. 7. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG does not exceed 15,000 ng/mL. 8. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 1,800 ng/mL. 9. The method of claim 8, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 3,000 ng/mL. 10. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 1,800 but does not exceed 15,000 ng/mL. 11. The method of claim 10, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 3,000 but does not exceed 15,000 ng/mL. 12. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AG does not exceed 2,000 ng/mL. 13. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AG is greater than 500 ng/mL. 14. The method of claim 13, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AG is greater than 900 ng/mL. 15. The method of claim 1, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AG is greater than 500 but does not exceed 2,000 ng/mL. 16. The method of claim 15, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AG is greater than 900 ng/mL but does not exceed 2,000 ng/mL. 17. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AAG or 17-AG that results in a combined AUCtotal of 17-AAG and 17-AG per dose in the range of about 17,500 ng/mL*h to about 43,000 ng/mL*h, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AAG or an equivalent amount of 17-AG. 18. The method of claim 17, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG does not exceed 15,000 ng/mL or the Cmax of 17-AG does not exceed 2,000 ng/mL. 19. The method of claim 17, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 1,800 ng/mL or the Cmax of 17-AG is greater than 500 ng/mL. 20. The method of claim 19, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 3,000 ng/mL or the Cmax of 17-AG is greater than 900 ng/mL. 21. The method of claim 17, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 1,800 but does not exceed 15,000 ng/mL or the Cmax of 17-AG is greater than 500 but does not exceed 2,000 ng/mL. 22. The method of claim 21, wherein said dose is administered at a rate and frequency such that the Cmax of 17-AAG is greater than 3,000 but does not exceed 15,000 ng/mL or the Cmax of 17-AG is greater than 900 but does not exceed 2,000 ng/mL. 23. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AAG that results in a Terminal T1/2 of 17-AAG in the range of 3 to 4.5 h, and wherein said therapeutically effective dose is in a range of between about 275 and about 420 mg/m2 of 17-AAG, or an equivalent amount of 17-AG. 24. The method of claim 23, wherein said dose administered results in an AUCtotal of 17-AAG per dose in the range of about 12,500 ng/mL*h to about 25,000 ng/mL*h. 25. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AG that results in a Terminal T1/2 of 17-AG in the range of 4 to 7 h, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AG. 26. The method of claim 25, wherein said dose results in an AUCtotal of 17-AG per dose in the range of about 5,000 to about 18,000 ng/mL*h. 27. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AAG that results in a Volume of distribution Vz of 17-AAG in the range of 100 to 270 L, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AAG. 28. The method of claim 27, wherein said dose results in an AUCtotal of 17-AAG per dose in the range of about 12,500 to about 25,000 ng/mL*h. 29. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AAG that results in a Clearance of 17-AAG in the range of 30 to 50 L/h, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AAG. 30. The method of claim 29, wherein said dose results in an AUCtotal of 17-AAG per dose in the range of about 12,500 to about 25,000 ng/mL*h. 31. A method of treating MM in a subject in need of such treatment, comprising the step of administering to said subject a therapeutically effective dose of 17-AAG that results in a Volume of distribution VSS of 17-AAG in the range of 100 to 150 L, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m2 of 17-AAG. 32. The method of claim 31, wherein said dose results in an AUCtotai of 17-AAG per dose in the range of about 12,500 to about 25,000 ng/mL*h. 33. The method of claim 1, wherein said administering step results in an induction of HSP70 in the peripheral blood mononuclear cells of said subject. 34. The method of claim 33, wherein said induction of HSP70 is observable one day after said administering step. 35. The method of claim 1, wherein said administering step results in an increase of apoptosis of CD 138+ cells among the bone marrow aspirate cells of said subject. 36. The method of claim 35, wherein said increase of apoptosis of CD138+ cells is observable four hours after said administering step. 37. The method of claim 1, wherein said administering step results in a decrease of total AKT in bone marrow aspirate cells of said subject. 38. The method of claim 37, wherein said decrease of total AKT is observable four hours after said administering step.